Welcome to our dedicated page for Legend Biotech SEC filings (Ticker: LEGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Legend Biotech Corporation (NASDAQ: LEGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a foreign private issuer. Legend Biotech files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together outline its financial performance, cell therapy pipeline, and key business developments.
In these filings, Legend Biotech presents unaudited interim condensed consolidated financial statements, including statements of profit or loss, financial position, changes in equity, and cash flows. Investors can review details on license revenue, collaboration revenue related to CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), research and development expenses, selling and distribution expenses, and collaboration funding arrangements. Management’s Discussion and Analysis (MD&A), often attached as exhibits to Form 6‑K, provides narrative context around revenue drivers, cost trends, and liquidity.
Filings also capture clinical and regulatory milestones. Recent 6‑Ks incorporate press releases on CARTITUDE‑1, CARTITUDE‑4, and CARTITUDE‑6 study updates, FDA and European Commission label changes for CARVYKTI, and early data from programs such as LUCAR‑G39D, LB2102, and LB1908. Additional 6‑Ks describe agreements with Janssen for component and product supply, preliminary sales figures for CARVYKTI, and participation in major scientific and investor conferences.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 6‑K and 20‑F filings, helping users quickly identify information on revenue composition, cell therapy pipeline status, collaboration structures, and risk disclosures. Real‑time ingestion of EDGAR updates ensures that new Legend Biotech filings, including any Form 6‑K related to financial results or material agreements, appear promptly.
Users can also monitor equity and compensation-related disclosures via Legend Biotech’s registration statements on Form S‑8, as referenced in its 6‑K reports, and review how these interact with share‑based compensation expenses reported in the financial statements. While Legend Biotech does not file Forms 3, 4, and 5 as a U.S. domestic issuer would, this page centralizes its available SEC reporting so investors can follow the company’s development as a global cell therapy business.
Legend Biotech reported total revenue of $255.1 million for the three months ended June 30, 2025 and $450.1 million for the six months, driven primarily by collaboration revenue (CARVYKTI) which rose to $219.7 million in Q2 and $405.3 million for H1. License revenue fell year-over-year due to timing of Janssen milestones, with license revenue of $35.3 million in Q2 versus $90.8 million a year earlier.
The company recorded a wider net loss of $125.4 million in Q2 and $226.3 million for H1; the MD&A attributes a large portion of the deterioration to unrealized foreign exchange losses (other expense of $108.1 million in Q2, $162.6 million in H1). Liquidity remains substantial with $266.6 million cash and $701.0 million time deposits (~$1.0 billion total). Management also reports CARVYKTI net trade sales of approximately $439 million and over 7,500 patients treated. Adjusted net income (non-IFRS) was $10.1 million in Q2 (ANI per share $0.03), illustrating the impact of excluding unrealized FX and certain non-cash items.
Legend Biotech Corp. (LEGN) filed a Form 144 indicating the proposed sale of 642 American Depositary Shares (ADS)—acquired through restricted-stock vesting on 03/20/2025 and valued at roughly $28,890—through Fidelity Brokerage Services. The seller plans to execute the trade on or about 07/23/2025 on NASDAQ. No other sales have occurred in the past three months, and the filing states that 367.3 million shares are outstanding.
The notice is routine: it simply pre-clears a small disposition under SEC Rule 144. The stake represents 0.00017% of shares outstanding, signalling no material change to ownership structure or to the investment thesis. The seller attests to having no undisclosed adverse information and, if relying on Rule 10b5-1, certifies plan adoption.
Legend Biotech (LEGN) filed a Form 6-K disclosing preliminary product-level revenue for its BCMA-directed CAR-T therapy, CARVYKTI. Janssen, the commercial partner, reported ≈US$439 million in net trade sales for the June-quarter 2025. Legend has not independently verified the figure and must still complete its own Q2 financial statements; the number could change once gross-to-net adjustments, profit-share calculations and auditor review are finalized.
The filing contains no P&L, cash-flow or margin data, but it does signal continued demand expansion only 2-years post-launch. Management reminds investors that revenue recognition, gross profit and royalty split will be determined during the normal close process. Forward-looking-statement language highlights usual development, regulatory and competitive risks and points users to the 2024 Form 20-F risk factors.
- The disclosed sales are informational, not yet audited.
- No guidance update or comparative growth metrics were provided.
- The filing is automatically incorporated into Legend’s existing F-3 and S-8 registration statements.
Legend Biotech Corporation insider Patrick Casey has filed Form 144 indicating intent to sell 1,000 American Depositary Shares (ADS) through Fidelity Brokerage Services. The proposed sale has an aggregate market value of $33,234.
The securities to be sold were originally acquired on June 20, 2022 through restricted stock vesting as compensation. The filing indicates that Casey has previously sold 1,000 ADS on June 6, 2025, for gross proceeds of $32,320.
Key transaction details:
- Total outstanding shares: 367,298,315
- Planned sale date: June 26, 2025
- Trading venue: NASDAQ
- Average price per share: $33.23
This Form 144 represents a standard insider sale notification, required when affiliates intend to sell restricted or control securities, and affirms no knowledge of undisclosed material adverse information.
Legend Biotech Corporation (NASDAQ: LEGN) has filed a Form 144 indicating a proposed insider sale of American Depositary Shares (ADS). According to the notice, the reporting shareholder plans to sell 11,810 ADS through Fidelity Brokerage Services on or about 24 June 2025. At the reference market price used in the filing, the transaction is valued at roughly $408,600. The sale represents an immaterial 0.003 % of the company’s 367.3 million ADS outstanding, suggesting limited direct impact on the public float.
The securities to be sold stem from restricted stock that vested on 20 June 2025 as part of the filer’s compensation package. Form 144 data also disclose prior sales by the same individual—4,064 ADS on 25 March 2025 for $143,371 and 6,548 ADS on 1 May 2025 for $226,233. Cumulatively, the filer has disposed of 10,612 ADS (≈$369,604) in the past three months, and the new planned trade will bring three-month total dispositions to 22,422 ADS worth about $778,000.
The filing includes the standard representation that the seller is unaware of any undisclosed material adverse information. No details about the filer’s position, trading plan status, or reason for the sale are provided. While insider sales can raise governance questions, the small size relative to capitalization and the routine vesting-related nature of the shares suggest limited financial significance for shareholders.
Legend Biotech Corporation (LEGN) – Form 144 filing
The filing, marked as LIVE, notifies the SEC of a proposed Rule 144 sale of 307 American Depositary Shares (ADS), valued at approximately $10,551.59. Fidelity Brokerage Services LLC is listed as broker, and the sale is expected to occur on or about 24 June 2025 on NASDAQ.
The ADS were acquired on 20 June 2025 through the vesting of restricted stock awarded as compensation. Outstanding ADS total 367,298,315; therefore, the planned disposition represents less than 0.0001 % of shares outstanding, indicating an immaterial effect on float or control.
The filer, identified in prior activity as Corazon Sanders, previously sold an identical lot of 307 ADS on 25 March 2025 for gross proceeds of $11,153.31. No relationship to the issuer, 10b5-1 plan details, or additional insider roles are disclosed. The signer attests to possessing no undisclosed material adverse information.